Skip to main content
main-content

29-06-2017 | Breast cancer | Article

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

Eljertsen B et al. J Clin Oncol 2017; 35(23): 2639-2646. doi:10.1200/JCO.2017.72.3494

Please log in to get access to this content

Related topics